4-amino-6-[2-(5-bromopyrimidin-2-yloxy)ethoxy]-5-(2-methoxyphenoxy)-2-morpholinopyrimidine | 184779-23-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-amino-6-[2-(5-bromopyrimidin-2-yloxy)ethoxy]-5-(2-methoxyphenoxy)-2-morpholinopyrimidine
• 英文别名: 6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-methoxyphenoxy)-2-morpholin-4-ylpyrimidin-4-amine
• CAS: 184779-23-5
• 化学式: C₂₁H₂₃BrN₆O₅
• 分子量: 519.355
• InChiKey: SKZZNPLXZAVKGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  4-amino-6-[2-(5-bromopyrimidin-2-yloxy)ethoxy]-5-(2-methoxyphenoxy)-2-morpholinopyrimidine 生成 N-{6-[2-(5-Bromopyrimidin-2-yloxy)ethoxy]-5-(2-methoxyphenoxy)-2-morpholinopyrimidin-4-yl}-2-naphthalenesulfonamide
  参考文献：
  名称：

  Sulfonamide derivative and process for preparing the same

  摘要：

  新型磺胺衍生物的化学式如下：##STR1##其中环A和环B是取代或未取代的单环、双环或三环碳氢化合物，或取代或未取代的杂环基团，Q是单键，-O-，-S-，-SO-，-SO.sub.2-或-CH.sub.2-，Y是-0-，-S-或-NH-，Alk是较低的烷基或烯基，Z是-O-或-NH-，R是取代或未取代的芳香杂环或芳基，R.sup.1是H，取代或未取代的氨基，取代或未取代的较低烷基、烯基、炔基、取代或未取代的较低烷硫基或烷氧基，或取代或未取代的杂环基团或芳基，或其药用盐，这些化合物在预防或治疗与内皮素活性相关的疾病方面具有用途，如高血压、肺动脉高压、肾高血压、雷诺病、支气管哮喘、胃溃疡、慢性心力衰竭等。

  公开号：

  US05739333A1

文献信息

• Novel arylethene-sulfonamides
  申请人：——

  公开号：US20030220359A1

  公开（公告）日：2003-11-27

  The invention relates to novel aryl-ethene-sulfonamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

  这项发明涉及新颖的芳基乙烯磺酰胺及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。
• Novel sulfamides and their use as endothelin receptor antagonists
  申请人：——

  公开号：US20040077670A1

  公开（公告）日：2004-04-22

  The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

  本发明涉及新型磺酰胺及其在制备药物组合物中作为活性成分的应用。该发明还涉及相关方面，包括化合物的制备过程、含有其中一种或多种化合物的药物组合物，以及它们作为内皮素受体拮抗剂的应用。
• [EN] NOVEL SULFAMIDES AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX SULFAMIDES ET LEUR UTILISATION COMME ANTAGONISTES DU RECEPTEUR DE L'ENDOTHELINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2002053557A1

  公开（公告）日：2002-07-11

  The invention relates to novel sulfamides of general formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

  本发明涉及一种新型一般式（I）的磺胺类化合物，以及它们在制备药物组合物的活性成分中的应用。本发明还涉及相关方面，包括化合物的制备过程，含有其中一种或多种化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。
• Novel sulfamides
  申请人：Bolli Martin

  公开号：US20060178365A1

  公开（公告）日：2006-08-10

  The invention relates to novel sulfamides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

  本发明涉及新型磺酰胺及其在制备药物组合物中作为活性成分的用途。本发明还涉及相关方面，包括合成这些化合物的过程、含有这些化合物中的一个或多个的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。
• Novel Sulfamides and their use as endothelin receptor antagonists
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1693372A1

  公开（公告）日：2006-08-23

  The invention relates to novel sulfamides of the general formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.

  本发明涉及通式（I）的新型氨基磺酸盐及其在制备药物组合物中作为活性成分的用途。本发明还涉及相关方面，包括制备这些化合物的工艺、含有一种或多种这些化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。